Technology | 2016.05.18
Bayer, ERS announce licensing agreement for genome-editing patents - BioPharma-Reporter.com
| BioPharma-Reporter.com | Bayer, ERS announce licensing agreement for genome- editing patents BioPharma-Reporter.com As Biopharma-Reporter previously reported , CRISPR-Cas9 is a tool for gene editing that can be faster and more precise that traditional gene editing options. The technology has the potential to eliminate orphan disease, according to Jim Mellon , a ... Bayer and ERS Genomics Announce Licensing Agreement for Genome Editing Patents Bayer strengthens position with gene editing technology with patent license deal Bayer takes deeper inroads into CRISPR tech with new deal |
For more information, please visit
http://news.google.com/news/url?sa=t&fd=[...]/Bayer-ERS-announce-licensing-
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1569
Instagram is adding automatic in-app text translation - The Verge views: 1507